These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 34407972)

  • 1. Upregulation of C/EBPα Inhibits Suppressive Activity of Myeloid Cells and Potentiates Antitumor Response in Mice and Patients with Cancer.
    Hashimoto A; Sarker D; Reebye V; Jarvis S; Sodergren MH; Kossenkov A; Sanseviero E; Raulf N; Vasara J; Andrikakou P; Meyer T; Huang KW; Plummer R; Chee CE; Spalding D; Pai M; Khan S; Pinato DJ; Sharma R; Basu B; Palmer D; Ma YT; Evans J; Habib R; Martirosyan A; Elasri N; Reynaud A; Rossi JJ; Cobbold M; Habib NA; Gabrilovich DI
    Clin Cancer Res; 2021 Nov; 27(21):5961-5978. PubMed ID: 34407972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial.
    Sarker D; Plummer R; Meyer T; Sodergren MH; Basu B; Chee CE; Huang KW; Palmer DH; Ma YT; Evans TRJ; Spalding DRC; Pai M; Sharma R; Pinato DJ; Spicer J; Hunter S; Kwatra V; Nicholls JP; Collin D; Nutbrown R; Glenny H; Fairbairn S; Reebye V; Voutila J; Dorman S; Andrikakou P; Lloyd P; Felstead S; Vasara J; Habib R; Wood C; Saetrom P; Huber HE; Blakey DC; Rossi JJ; Habib N
    Clin Cancer Res; 2020 Aug; 26(15):3936-3946. PubMed ID: 32357963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MTL-CEBPA Combined with Immunotherapy or RFA Enhances Immunological Anti-Tumor Response in Preclinical Models.
    Huang KW; Tan CP; Reebye V; Chee CE; Zacharoulis D; Habib R; Blakey DC; Rossi JJ; Habib N; Sodergren MH
    Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory Activity of MTL-CEBPA, a Small Activating RNA Drug, in LPS-Stimulated Monocytes and Humanized Mice.
    Zhou J; Li H; Xia X; Herrera A; Pollock N; Reebye V; Sodergren MH; Dorman S; Littman BH; Doogan D; Huang KW; Habib R; Blakey D; Habib NA; Rossi JJ
    Mol Ther; 2019 May; 27(5):999-1016. PubMed ID: 30852139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis.
    Deng X; Li X; Guo X; Lu Y; Xie Y; Huang X; Lin J; Tan W; Wang C
    Neoplasia; 2022 Jun; 28():100788. PubMed ID: 35378464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of MTL-CEBPA: Small Activating RNA Drug for Hepatocellular Carcinoma.
    Setten RL; Lightfoot HL; Habib NA; Rossi JJ
    Curr Pharm Biotechnol; 2018; 19(8):611-621. PubMed ID: 29886828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription.
    Du M; Wang M; Liu M; Fu S; Lin Y; Huo Y; Yu J; Yu X; Wang C; Xiao H; Wang L
    J Exp Clin Cancer Res; 2024 Mar; 43(1):79. PubMed ID: 38475919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer.
    Reebye V; Huang KW; Lin V; Jarvis S; Cutilas P; Dorman S; Ciriello S; Andrikakou P; Voutila J; Saetrom P; Mintz PJ; Reccia I; Rossi JJ; Huber H; Habib R; Kostomitsopoulos N; Blakey DC; Habib NA
    Oncogene; 2018 Jun; 37(24):3216-3228. PubMed ID: 29511346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma.
    Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF
    J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual negative roles of C/EBPα in the expansion and pro-tumor functions of MDSCs.
    Mackert JR; Qu P; Min Y; Johnson PF; Yang L; Lin PC
    Sci Rep; 2017 Oct; 7(1):14048. PubMed ID: 29070836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Liver Cancer by C/EBPA saRNA.
    Zhao X; Voutila J; Ghobrial S; Habib NA; Reebye V
    Adv Exp Med Biol; 2017; 983():189-194. PubMed ID: 28639200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
    Kapanadze T; Gamrekelashvili J; Ma C; Chan C; Zhao F; Hewitt S; Zender L; Kapoor V; Felsher DW; Manns MP; Korangy F; Greten TF
    J Hepatol; 2013 Nov; 59(5):1007-13. PubMed ID: 23796475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-486 promotes proliferation and suppresses apoptosis in myeloid cells by targeting Cebpa in vitro.
    Jiang J; Gao Q; Gong Y; Huang L; Lin H; Zhou X; Liang X; Guo W
    Cancer Med; 2018 Sep; 7(9):4627-4638. PubMed ID: 30073773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
    Chen Y; Ramjiawan RR; Reiberger T; Ng MR; Hato T; Huang Y; Ochiai H; Kitahara S; Unan EC; Reddy TP; Fan C; Huang P; Bardeesy N; Zhu AX; Jain RK; Duda DG
    Hepatology; 2015 May; 61(5):1591-602. PubMed ID: 25529917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation.
    Lu GD; Leung CH; Yan B; Tan CM; Low SY; Aung MO; Salto-Tellez M; Lim SG; Hooi SC
    Gastroenterology; 2010 Aug; 139(2):632-43, 643.e1-4. PubMed ID: 20347819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma.
    Zhao X; Reebye V; Hitchen P; Fan J; Jiang H; Sætrom P; Rossi J; Habib NA; Huang KW
    Oncogene; 2019 May; 38(18):3446-3457. PubMed ID: 30643190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer.
    Voutila J; Reebye V; Roberts TC; Protopapa P; Andrikakou P; Blakey DC; Habib R; Huber H; Saetrom P; Rossi JJ; Habib NA
    Mol Ther; 2017 Dec; 25(12):2705-2714. PubMed ID: 28882451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An autonomous CEBPA enhancer specific for myeloid-lineage priming and neutrophilic differentiation.
    Avellino R; Havermans M; Erpelinck C; Sanders MA; Hoogenboezem R; van de Werken HJ; Rombouts E; van Lom K; van Strien PM; Gebhard C; Rehli M; Pimanda J; Beck D; Erkeland S; Kuiken T; de Looper H; Gröschel S; Touw I; Bindels E; Delwel R
    Blood; 2016 Jun; 127(24):2991-3003. PubMed ID: 26966090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.